Dr. Jason Hafron discusses developments in research for non-muscle-invasive bladder cancer with Targeted Oncology
IN THIS INTERVIEW: Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer. Hafron is the chief medical officer and medical director of clinical research at Michigan Institute of Urology, and a professor of urology at William Beaumont School of Medicine, Oakland University.
